Novartis, Glenmark, Centrient Act To Tackle COVID-19 Crisis
As Beximco Generates Employment With PPE Manufacturing
While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.
You may also be interested in...
The Phase III clinical trials of Glenmark’s FabiFlu demonstrate that the oral antiviral could prevent mild and moderate Covid-19 patients from progressing to acute respiratory distress syndrome or dying. Glenmark plans to release the clinical trial data soon.
Centrient has declared itself one of the first companies to announce progress in achieving Predicted No-Effect Concentration discharge targets for the largest part of its antibiotics – the firm’s semi-synthetic penicillin active pharmaceutical ingredients portfolio. In addition, 97% of Centrient’s SSP finished-dose formulation products are also PNEC compliant, according to the firm.
The WHO’s “Solidarity” trial investigators have decided to interrupt the trials with immediate effect since the clinical trial found that hydroxychloroquine and lopinavir/ritonavir “produced little or no reduction in the mortality of the hospitalized COVID-19 patients.”